Biofrontera AG BIFRF

Company Overview

Biofrontera AG is a German biopharmaceutical company focused on dermatology, with an emphasis on the treatment of non-melanoma skin cancers and chronic skin conditions. The company develops and commercializes prescription drugs and medical devices, primarily in the field of photodynamic therapy (PDT). Its core business centers on the commercialization of aminolevulinic acid-based therapies used for actinic keratosis, a precancerous skin condition caused by long-term sun exposure. Biofrontera operates within the broader pharmaceutical, dermatology, and medical technology industries.

The company’s primary revenue drivers include sales of its PDT drug products and associated medical lamps used during treatment procedures. Its flagship product, Ameluz®, has been approved in multiple jurisdictions for actinic keratosis treatment and certain forms of basal cell carcinoma when used with PDT. Biofrontera’s customer base primarily includes dermatologists, dermatology clinics, and healthcare providers across Europe and North America. The company was founded in 1997 in Germany and evolved from a biotechnology research-focused organization into a commercially oriented dermatology company with international operations. Biofrontera has sought to differentiate itself through specialized expertise in PDT and a combination of pharmaceutical and device-based treatment offerings.